Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.

Date publication

janvier 2017

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent , Dr COUDERT Bruno , Pr COUTANT Charles , Pr FUMOLEAU Pierre , Dr DESMOULINS Isabelle , Dr CHARON-BARRA Céline

Tous les auteurs :
Jankowski C, Guiu S, Cortet M, Charon-Barra C, Desmoulins I, Lorgis V, Arnould L, Fumoleau P, Coudert B, Rouzier R, Coutant C, Reyal F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27807808

Résumé

The aim of this study was to assess the Institut Gustave Roussy/M.D. Anderson Cancer Center (IGR/MDACC) nomogram in predicting pathologic complete response (pCR) to preoperative chemotherapy in a cohort of human epidermal growth factor receptor 2 (HER2)-positive tumors treated with preoperative chemotherapy with trastuzumab. We then combine clinical and pathological variables associated with pCR into a new nomogram specific to HER2-positive tumors treated by preoperative chemotherapy with trastuzumab.

Mots clés

Breast cancer, HER2, Neoadjuvant chemotherapy, Predictive factors

Référence

Breast Cancer Res. Treat.. 2017 Jan;161(1):73-81